The effect of radioiodine therapy on blood cell count in patients with differentiated thyroid cancer
© 2023. The Author(s), under exclusive licence to Hellenic Endocrine Society..
PURPOSE: This study aimed to investigate the long-term effects of radioiodine treatment (RAI) on blood cell counts in patients with differentiated thyroid cancer (DTC) and to describe the characteristics of patients at high risk for blood cell count abnormalities.
METHODS: The study included patients with DTC who underwent RAI treatment between 2007 and 2017. Patients with regular complete blood counts for at least 5 years were included, while those with diseases or treatments that could influence blood count parameters were excluded. Blood cell count abnormalities were defined according to the Common Terminology Criteria for Adverse Events version 5.0, and factors influencing these abnormalities were examined.
RESULTS: A total of 225 patients were analyzed. The mean age at diagnosis was 45.8 ± 13.9 years, and 76.5% of patients were female. In the first year after RAI, leukocyte, neutrophil, and lymphocyte counts were significantly reduced compared with baseline values. The leukocyte and neutrophil counts returned to baseline values by the third year, while the decrease in lymphocytes continued until the fifth year. Blood cell count abnormalities developed in 16 patients (7.1%) within the first year after RAI. Risk factors for blood cell count abnormalities within the first year after RAI included male sex, older age, T4, N1, and M1 disease, as well as higher RAI doses. In logistic regression analysis, only RAI dose remained independently associated with blood cell count abnormalities.
CONCLUSION: These results suggest an association between RAI dose and blood cell count abnormalities, characterized by mild lymphopenia, and indicate that the risk of mild lymphopenia persists over time. Careful consideration should be given when planning high-dose RAI for patients at a high risk of blood cell count abnormalities, such as males with metastatic disease and of advanced age.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Hormones (Athens, Greece) - 22(2023), 4 vom: 09. Dez., Seite 595-602 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Demir, Ahmet Numan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blood cell counts |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s42000-023-00479-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361019106 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361019106 | ||
| 003 | DE-627 | ||
| 005 | 20240214232751.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s42000-023-00479-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM361019106 | ||
| 035 | |a (NLM)37603221 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Demir, Ahmet Numan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The effect of radioiodine therapy on blood cell count in patients with differentiated thyroid cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Hellenic Endocrine Society. | ||
| 520 | |a PURPOSE: This study aimed to investigate the long-term effects of radioiodine treatment (RAI) on blood cell counts in patients with differentiated thyroid cancer (DTC) and to describe the characteristics of patients at high risk for blood cell count abnormalities | ||
| 520 | |a METHODS: The study included patients with DTC who underwent RAI treatment between 2007 and 2017. Patients with regular complete blood counts for at least 5 years were included, while those with diseases or treatments that could influence blood count parameters were excluded. Blood cell count abnormalities were defined according to the Common Terminology Criteria for Adverse Events version 5.0, and factors influencing these abnormalities were examined | ||
| 520 | |a RESULTS: A total of 225 patients were analyzed. The mean age at diagnosis was 45.8 ± 13.9 years, and 76.5% of patients were female. In the first year after RAI, leukocyte, neutrophil, and lymphocyte counts were significantly reduced compared with baseline values. The leukocyte and neutrophil counts returned to baseline values by the third year, while the decrease in lymphocytes continued until the fifth year. Blood cell count abnormalities developed in 16 patients (7.1%) within the first year after RAI. Risk factors for blood cell count abnormalities within the first year after RAI included male sex, older age, T4, N1, and M1 disease, as well as higher RAI doses. In logistic regression analysis, only RAI dose remained independently associated with blood cell count abnormalities | ||
| 520 | |a CONCLUSION: These results suggest an association between RAI dose and blood cell count abnormalities, characterized by mild lymphopenia, and indicate that the risk of mild lymphopenia persists over time. Careful consideration should be given when planning high-dose RAI for patients at a high risk of blood cell count abnormalities, such as males with metastatic disease and of advanced age | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Blood cell counts | |
| 650 | 4 | |a Differentiated thyroid cancer | |
| 650 | 4 | |a Lymphopenia | |
| 650 | 4 | |a Radioiodine | |
| 650 | 7 | |a Iodine Radioisotopes |2 NLM | |
| 700 | 1 | |a Kara, Zehra |e verfasserin |4 aut | |
| 700 | 1 | |a Sulu, Cem |e verfasserin |4 aut | |
| 700 | 1 | |a Uysal, Serhat |e verfasserin |4 aut | |
| 700 | 1 | |a Zulfaliyeva, Guldana |e verfasserin |4 aut | |
| 700 | 1 | |a Atar, Oznur Aydin |e verfasserin |4 aut | |
| 700 | 1 | |a Valikhanova, Nahida |e verfasserin |4 aut | |
| 700 | 1 | |a Ozturk, Tulin |e verfasserin |4 aut | |
| 700 | 1 | |a Ozkaya, Hande Mefkure |e verfasserin |4 aut | |
| 700 | 1 | |a Damci, Taner |e verfasserin |4 aut | |
| 700 | 1 | |a Gonen, Mustafa Sait |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hormones (Athens, Greece) |d 2002 |g 22(2023), 4 vom: 09. Dez., Seite 595-602 |w (DE-627)NLM161628591 |x 2520-8721 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:4 |g day:09 |g month:12 |g pages:595-602 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s42000-023-00479-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 4 |b 09 |c 12 |h 595-602 | ||